Sildenafil Ameliorates Effects of Inhaled Nitric Oxide Withdrawal
Abstract
(Atz) Assistant in Cardiology, Children's Hospital; Instructor in Pediatrics, Harvard Medical School.(Wessel) Director, Cardiac Intensive Care Unit, Children's Hospital; Associate Professor of Pediatrics (Anaesthesia), Harvard Medical School.From the Department of Cardiology, Children's Hospital, and the Departments of Pediatrics and Anaesthesia, Harvard Medical School, Boston, Massachusetts. Submitted for publication September 16, 1998. Accepted for publication February 18, 1999. Dr. Atz is supported by an award from the National Institutes of Child Health and Human Development (# P30HD27805) and a grant from the United States Food and Drug Administration. Dr. Wessel is supported by grants from the United States Food and Drug Administration (# FDR-001316–01) and the Research Endowment of Children's Hospital (# 89430–02).Address reprint requests to Dr. Wessel: Cardiac ICU Office, Children's Hospital, 300 Longwood Avenue, Farley 653, Boston, Massachussetts 02115. Address electronic mail to:[email protected] nitric oxide (NO) is a selective pulmonary vasodilator with therapeutic importance in pulmonary hypertension and respiratory failure. NO increases intracellular cyclic guanosine monophosphate (cGMP), which stimulates smooth muscle relaxation. Phosphodiesterase type 5 (PDE5) is found in high concentrations in the lung and contributes substantially to cGMP degradation within vascular smooth muscle. [1] Abrupt discontinuation of NO may be complicated by…
Read the paper
Related studies
- 2024 update in heart failure
- Vascular involvement in idiopathic pulmonary fibrosis
- A novel technique- subendometrial autologous platelet rich plasma injection in patients with unresponsive thin endometrium undergoing frozen-thawed embryo transfer: a prospective cohort study
- Does metformin prolong pregnancy in preterm pre-eclampsia? A study protocol for a South African, hospital-based double-blind, randomised, placebo-controlled trial
- Combined Pulmonary Fibrosis and Emphysema (CPFE): A "New" Smoking-Related Interstitial Lung Disease (ILD)
- Impact of an acute 1-month cannabidiol treatment on pain and inflammation after a long bone fracture: a triple-blind randomised, placebo-controlled, clinical trial protocol
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.